Drug-Induced Osteoporosis Risk Signals from FAERS and WHO Vigibase, 2014-2025

55,895 deduplicated osteoporosis-related adverse event reports from the FDA Adverse Event Reporting System (FAERS) between Q1 2014 and Q1 2025. The dataset was created by Wenbin Gao and last updated in April 2026, using disproportionality analysis and regression to identify high-risk drugs and demographic factors, with validation against the WHO Vigibase.

Use Cases

• Identifying high-risk medications for osteoporosis based on disproportionality analysis signals.
• Analyzing demographic risk factors like age and sex from multivariate regression results.
• Studying adverse event onset time patterns for specific drugs mentioned in the results.
• Validating pharmacovigilance signals from one database against another external source.

Strengths

• Includes 55,895 deduplicated case reports.
• Covers a time range from Q1 2014 to Q1 2025.
• Uses multiple statistical methods (ROR, PRR, MGPS, BCPNN, LASSO, multivariate regression) for signal detection.
• Performs external validation using the WHO Vigibase database.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the underlying raw data tables is unknown, which may limit suitability assessment.
• Data may reflect reporting bias inherent to spontaneous adverse event reporting systems.

Provenance

Source

FDA Adverse Event Reporting System (FAERS) and WHO Vigibase.

Collection Method

Deduplication and statistical analysis of adverse event reports.

Time Range

Q1 2014 to Q1 2025.

Freshness

Last updated 2026-04-13 04:35:33; freshness should be verified.

Geography

Likely global, based on the international scope of FAERS and WHO Vigibase.